Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
| Specialty Retail Industry | Consumer Discretionary Sector | Joseph C. Papa Jr. CEO | XMIL Exchange | US29089Q1058 ISIN |
| US Country | 900 Employees | - Last Dividend | - Last Split | 15 Nov 2006 IPO Date |
Emergent BioSolutions Inc. is a life sciences company that specializes in offering preparedness and response solutions against a range of public health threats, including accidental, deliberate, and naturally occurring ones, within the United States. With its foundation dating back to 1998, the company is based in Gaithersburg, Maryland. Emergent BioSolutions Inc. is dedicated to safeguarding public health through its comprehensive portfolio of products designed to combat serious health threats such as opioid overdose, cholera, typhoid fever, anthrax, smallpox, Ebola, and exposure to various chemical and biological warfare agents. In addition to its product offerings, Emergent BioSolutions Inc. extends its expertise through contract development and manufacturing services, emphasizing drug substance and product manufacturing, packaging, technology transfer, and process and analytical development.